5 results about "Allergic response" patented technology

Tree pollen allergy is a seasonal allergy caused by various tree pollens suspended in the air. This allergy affects a significant proportion of the population, particularly in Europe and North America, and is characterized by symptoms such as sneezing, nasal congestion, runny nose, itchy or watery eyes, and throat inflammation. These symptoms typically occur in spring when trees such as birch, alder, hazel, and oak release pollen into the air. Tree pollen allergy is a type 1 hypersensitivity reaction mediated by immunoglobulin E (IgE) antibodies. This invention relates to antibodies and their antigen-binding fragments that bind to one or more tree pollen allergens, Bet v 1, Aln g 1, Cor a 1, and Que a 1, and inhibit the IgE-mediated allergic reaction.

The invention discloses an anti-nasal allergy gel production optimization method based on data analysis, particularly relates to the field of resource allocation and production optimization, and is used for solving the problems that in the existing anti-allergic gel production process, response to regional and seasonal demand changes is delayed, and raw material supply constraint and production line switching cost are difficult to collaboratively balance. According to the method, raw material supply chain data, market sales records and environmental allergen time sequence data are collected to construct a unified space-time associated data basis, the recurrent neural network is utilized to predict the anti-allergic response intensity in a future production cycle, and product dosage form preference weights are formed based on association rule mining. On the basis, various executable candidate production schemes are generated in combination with raw material inventory and delivery cycle constraints, and decision selection is further performed on the schemes according to the real-time state of a production line and switching cost, so that refined configuration and efficient execution of the production process of the anti-nasal allergy gel are realized.

The present invention relates to dihydrocyclopenta-isoquinoline-sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FcεRI receptor.

The disclosure provides for covalent dual-functional inhibitors of peanut allergic reactions where the inhibitors include a targeting moiety comprising a peanut allergen protein epitope or mimotope peptide sequence, a reactive functional group capable of forming a site-directed covalent bond to the amine moiety of a lysine amino acid of an allergen reactive immunoglobulin, and a variable length spacer comprising oligomers of ethylene glycol monomers, amino acids, saccharides, hydrocarbons, fluorinated hydrocarbons, or a combination thereof, wherein the 10 spacer is conjugated by one or more amide bonds to the TM and the FG.